Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.78
- Piotroski Score 8.00
- Grade Hold
- Symbol (DVA)
- Company DaVita Inc.
- Price $165.51
- Changes Percentage (0.83%)
- Change $1.37
- Day Low $163.76
- Day High $166.27
- Year High $168.50
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services to 16,000 patients in risk-based integrated care arrangements and 7,000 patients in other integrated care arrangements; vascular access services; clinical research programs; physician services; and comprehensive kidney care services. As of December 31, 2021, it provided dialysis and administrative services in the United States through a network of 2,815 outpatient dialysis centers serving approximately 203,100 patients; and operated 339 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 39,900 patients. Further, the company provides acute inpatient dialysis services in approximately 850 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/11/2025
- Fiscal Year End N/A
- Average Stock Price Target $131.00
- High Stock Price Target $150.00
- Low Stock Price Target $90.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $8.82
- Trailing P/E Ratio 16.23
- Forward P/E Ratio 16.23
- P/E Growth 16.23
- Net Income $691.54 M
Income Statement
Quarterly
Annual
Latest News of DVA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Advanced Micro Devices (AMD) Powers World's Fastest Supercomputer: El Capitan Achieves 1.742 Exaflops
The article discusses the rise of AI stocks on Wall Street, focusing on OpenAI's success and legal issues. Advanced Micro Devices (AMD) is highlighted for its AI advancements, including the developmen...
By Yahoo! Finance | 12 hours ago -
Advanced Micro Devices, Inc. (AMD) PCs Excluded from Upcoming Microsoft Windows AI Copilot Features, Limited to Snapdragon Devices
AI stocks are gaining momentum, attracting billions in investments. The European Central Bank warns of a potential AI asset price bubble, especially in the US market. Advanced Micro Devices, Inc. (AMD...
By Yahoo! Finance | 1 day ago -
Bio-Path Holdings Inc (BPTH) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial ...
CEO Peter Nielsen discussed the new clinical development program for BP 101 A targeting obesity and metabolic diseases, focusing on insulin resistance. Preclinical studies will assess its potential in...
By Yahoo! Finance | 1 day ago
